Shirley Ryan AbilityLab receives a USD 8.7 million NIH grant to fund clinical trials including Integrum’s e-OPRA Implant System
Mölndal, Sweden, June 8, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that Shirley Ryan AbilityLab – a top-ranked physical medicine and rehabilitation hospital based in Chicago, US – has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). The grant will be used to fund two clinical trials evaluating the function of Integrum’s e-OPRATM Implant System. It is anticipated that Integrum will receive up to USD 1.3 million during the program to support the study activities.
Shirley Ryan AbilityLab is a global leader in the field of bionics – the study of mechanical systems that mimic parts of living organisms. The NIH grant will be used to fund the first clinical program in the world combining osseointegration, targeted muscle reinnervation (TMR) and pattern-recognition control, using implanted electromyographic (EMG) sensors. Through the combination of these technologies, individuals who have experienced upper limb loss may recover lower arm functionality and sensation of touch.
The clinical trials aim to evaluate the comfort and function of the implanted electrodes of Integrum’s e-OPRATM Implant System in an in-home environment, as well as its functionality in providing sensory feedback to the central nervous system. Integrum will be supplying e-OPRA implant systems to Shirley Ryan AbilityLab, and surgeons at Northwestern Medicine will implant the devices and perform TMR surgery in eight study participants.
“The NIH grant awarded to Shirley Ryan AbilityLab equates to significant recognition from one of the world’s most prestigious research institutions, underscoring the potential of Integrum’s e-OPRA Implant System. We look forward to contributing to this important initiative that aims to validate our groundbreaking technology and hope to take it yet another step further toward potential marketing approval,” comments Rickard Brånemark, CEO of Integrum.
The grant is funded through the NIH’s UG3 and UH3 mechanisms, which are specifically targeted at translating groundbreaking neural technologies for patients.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-06-2023 08:00 CET.
For more information please contact:
Rickard Brånemark, CEO. Phone: +46 708 461061, E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO. Phone: +46 (0) 70 734 96 60, E-mail: jorgen.svanstrom@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser